Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss modern approaches to the management of multiple myeloma and review recent data presented at the 2021 ASCO Annual Meeting.
EP. 1: Overview of Newly Diagnosed Multiple MyelomaJuly 13th 2021
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.
EP. 2: Standard Induction for Newly Diagnosed Symptomatic MyelomaJuly 13th 2021
Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.
EP. 3: High-Risk Multiple Myeloma: Selecting Initial TherapyJuly 20th 2021
Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.
EP. 4: Improving Maintenance Therapy for MyelomaJuly 20th 2021
Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.
EP. 8: CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible MyelomaAugust 3rd 2021
Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.
EP. 10: Treatment of Relapsed/Refractory Myeloma: Novel AgentsAugust 10th 2021
Cristina Gasparetto, MD; Sagar Lonial, MD, FACP; Joseph Mikhael, MD; and Nina Shah, MD, discuss emerging agents available for the treatment of RRMM.
EP. 11: Role of BCMA-Targeted Agents in MyelomaAugust 17th 2021
Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.
EP. 13: CARTITUDE-1 and CARTITUDE-2 Trials in Multiple MyelomaAugust 24th 2021
Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.
EP. 14: Investigational Agents for Relapsed/Refractory MyelomaAugust 24th 2021
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.